by A new study examines whether a simple blood test can recognize 10 different types of cancer in its very early stage.
The test, which was illuminated and developed by prototype diagnostics, is looking for certain proteins in the blood that indicate that the immune system reacts to the first signs of the disease.
It is also examined whether it can see what kind of cancer a patient has.
The modernized study led by the unit in clinical studies in Southampton aims to recruit 1,000 patients, with 450 already participating.
Experts will remove samples of people with 10 fixed tumor types, including bladder, chest, lungs, prostate, ovaries, pancreas, esophagus and kidneys.
It also includes patients with colorectal tumors and melanoma, a kind of skin cancer.
Experts claim that it has been enlightened what other blood tests distinguish in order to recognize different cancer.
Professor Andy Davies, director of the Southampton Cancer Research UK and the National Institute for Health and Nursing Research Experimental Cancer Cancer Medicine Center, said: “Most current research on blood tests with several cancer focus on the detection of abnormal DNA that was released by cancer cells in the blood stream.
“However, this circulating tumor -dna cannot always be demonstrated in the very early stages of cancer.
“Instead, we consider the mirrors of certain proteins in the blood.
“We know that the body’s immune response, even in the earliest stages of cancer, can lead to higher mirrors of these proteins, and we believe that this is a good way to test early signs of the disease.”
The 72 -year -old Ian Robinson from Fawley in Hampshire was diagnosed with intestinal cancer after routine screening and has registered to take part in the modernized study.
The grandfather of five years said: “I sent the NHS intestine cancer screening kit. I think I had done four of them, usually with a negative result, but the youngest showed that there was a chance of cancer that was confirmed with a colonoscopy.
“There were no symptoms, no pain, nothing, so they would never know until it was much more advanced and therefore much more difficult to treat.
“Obviously the team helps me here, so I’m looking forward to participating and hopefully contributing to improve the way things are done.
“My mother died of cancer. I now have children and five grandchildren, so yes, research is absolutely important. The more cancer that can be identified as early as possible, future generations will obviously be the right way.”
Professor Andy Davies, director of the Southampton Cancer Research UK and National Institute for Health and Care Research Experimental Cancer Medicine Center, heads the modernized study (Southampton Clinical Studies Unit/Pa)
According to Cancer Research UK, there are around 385,000 new cases of cancer every year in Great Britain.
Dr. Victoria Goss, Associate Professor and Head of Early Diagnostic Research In the Unity Clinical Studies in Southampton, said: “If cancer are later diagnosed, the patient is often less available to patients.
“Early recognition of cancer means that treatment can begin earlier, which increases the likelihood of successful results for patients.
“The improvement of the early diagnosis is therefore a priority for us as a researcher and for the NHS.
“But currently there are only four screening programs in Great Britain and the screening has only been made for cancer. Therefore, we want to develop simple tests that may be able to take up the signs of several types of cancer, which offers the best possible chance of early, successful treatment.”
Dr. Emma Yates, co -founder and Chief Scientific Officer from Proteotype Diagnostics, said that preliminary studies explain that they “have a high degree of accuracy for the collection of cancer in its early stages”.
She added: “We are now working with Professor Davies and the Southampton Clinical Trials Unit team to test it in a much larger group of people to see if it is a useful early diagnosis tool.”
The modernized process is financed by the National Institute for Health and Care Research (NIHR) for innovation programs and the Office for Life Sciences.
It runs at five hospital locations in Hampshire and Dorset and will soon be opened in Manchester.
Dr. Kotryna Temcinait, head of research communication and commitment to The Charity Breast Cancer Now, said: “Early detection is our best weapon against breast cancer – fundamentally for saving more life from this devastating disease.
“And this exciting early research could have the future potential to diagnose earlier and faster breast cancer in the future.
“While we are waiting for the results of this study, there are some simple things that people can recognize in the past. This regularly includes their breasts and the acquisition of new or unusual changes that visit a family doctor and attend the breast -screening dates when invited.”
